RecruitingPhase 2NCT05941156
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Intervention
- Anti-CD56 CAR T(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05941156 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT05863234Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaHiroshima University Hospital